Bayer to Work With Dewpoint Therapeutics to Develop New Therapies
14 Noviembre 2019 - 08:02AM
Noticias Dow Jones
By Carlo Martuscelli
Bayer AG (BAYN.XE) said Thursday that it is investing up to $100
million to research new treatments for cardiovascular and
gynecological diseases with U.S. biotech Dewpoint Therapeutics.
The two companies signed an option, research and license
agreement, Bayer said. Under the terms of the deal it will use
Dewpoint's biomolecular condensates platform to drive research into
the disease areas.
Germany's Bayer also said that it will have the option to
exclusively license new therapy candidates developed from the
research activities.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
November 14, 2019 08:47 ET (13:47 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024